Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape. According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge. Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.” The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time. Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music. Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone. This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates. About Dr. Don Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression. Media Contact Dr. Don E: don@drdonmusic.com W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io

Commences building an RWA (Real-World Asset) token economy Maximizing Value Through Digitalization Using Cutting-Edge 3D Scanning Technology “SCAI” and RWA Indexing New York, NY – January 20, 2026 – (SeaPRwire) – VIVI PROJECT (formerly LEGENDARY HUMANITY) announces a major update and rebranding. The project utilizes the latest 3D scanning technology “SCAI” to digitally archive humanity’s cultural heritage, providing training data for AI and building a new token economy based on RWA (Real World Assets). Background and Project Evolution Previously, “LEGENDARY HUMANITY” aimed to digitize humanity’s greatest masterpieces using cutting-edge technology, teaching AI about “humanity’s magnificence” to preserve its value for future generations. With this update, the project is renamed “VIVI PROJECT.” Moving beyond mere archiving, it will challenge the creation of new value in the Web3 era as an “RWA token project” building a unique economic ecosystem backed by real-world assets (RWA). The Four Pillars of the “RWA Ecosystem” Provided by VIVI PROJECT Digitization via High-Precision 3D Scanning Technology “SCAI:DIGITAL LUMINOUS Technology” Digitizing humanity’s treasures and providing them as AI training data. Merging human wisdom with technological evolution. Adding RWA Value to VIVI COiN: Centered around the project token “VIVI COiN,” we plan to link RWA held by collectors partnered with “VIVI PROJECT” to enhance the project’s value.By using “LEGENDARY masterpieces” whose value appreciates over time as the foundation for “VIVI COiN,” we build a stable value base. Hybrid Digital & Physical Museum Collected RWAs will be displayed in both digital museums and physical exhibition facilities. Trading via the marketplace will also be enabled, enhancing liquidity as an asset. VIVI DAO’s “Buy-Back & Burn” Model The governing body, “VIVI DAO,” will use exhibition and sales revenue to implement “Buy-Back” and “Burn” of VIVI COiN. This will increase the token’s scarcity and promote long-term value appreciation. Future Outlook: Global Collection Partnerships The VIVI PROJECT is advancing the networking of collections held by global asset owners. As a first step, we have initiated the following partnerships and negotiations: LA MUSEUM: Holds one of the world’s largest legendary fashion collections, including Yves Saint Laurent, Comme des Garçons, Worlds End, Alexander McQueen, John Galliano, and Madison Martin Margiela. Major Trading Card Company: Negotiations have commenced with the world’s largest trading asset company. This will integrate Real-World Assets (RWAs) from diverse genres like fashion, art, and hobbies into the project, rapidly expanding the ecosystem. VIVI PROJECT Overview VIVI PROJECT is a next-generation platform that preserves and utilizes humanity’s greatest masterpieces in both digital and physical realms through the fusion of culture and technology. By indexing RWA, it defines new asset value in the Web3 era. Official Website: https://lhvivi.com Contact for Inquiries Contact: VIVI PROJECT PR Department Email: press@lhvivi.com

Mexico City, Mexico – January 10, 2026 – (SeaPRwire) – Excent Capital has announced the launch of a new incentive program for its global partner network, offering exclusive experiences connected to the 2026 World Cu as part of its ongoing commitment to long-term collaboration and partner engagement. The initiative is designed to recognise partner performance and strengthen relationships through experiences that go beyond traditional rewards. Depending on performance tiers, partners may qualify for packages that include match tickets, travel arrangements, accommodation, and curated experiences in the United States during the tournament. Rather than focusing solely on volume, the program is structured to encourage sustainable growth, strategic alignment, and continued collaboration between Excent Capital and its partners. The incentive tiers are linked to clearly defined performance benchmarks, ensuring transparency and consistency across regions. “We work very closely with our partners on a daily basis, and this initiative is a way to give something back that goes beyond numbers,” said Andrés Espinosa, Senior Business Development Manager at Excent Capital. The World Cup 2026 incentive program is open to eligible partners worldwide and will run until May 15. Participation details, performance criteria, and tier qualifications are communicated directly to partners through Excent Capital’s regional business development teams. About Excent Capital Excent Capital is a global trading broker offering access to a wide range of financial markets. Operating on proprietary, in-house developed technology, the company focuses on transparency, execution quality, and partner-driven growth, supporting partners through education, consistent market insight, and collaborative initiatives. Contact Information Organization: Excent Capital Contact Person: Ryccielli Ongaratto, Marketing Manager Email: support@excent.capital Website: https://excent.capital/